Vladimir Moiseyenko

13.1k total citations · 5 hit papers
142 papers, 8.1k citations indexed

About

Vladimir Moiseyenko is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Vladimir Moiseyenko has authored 142 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Oncology, 57 papers in Pulmonary and Respiratory Medicine and 34 papers in Cancer Research. Recurrent topics in Vladimir Moiseyenko's work include Colorectal Cancer Treatments and Studies (42 papers), Lung Cancer Treatments and Mutations (31 papers) and Gastric Cancer Management and Outcomes (22 papers). Vladimir Moiseyenko is often cited by papers focused on Colorectal Cancer Treatments and Studies (42 papers), Lung Cancer Treatments and Mutations (31 papers) and Gastric Cancer Management and Outcomes (22 papers). Vladimir Moiseyenko collaborates with scholars based in Russia, United States and United Kingdom. Vladimir Moiseyenko's co-authors include Eric Van Cutsem, Jaffer A. Ajani, M Fodor, Alejandro Majlis, Sergei Tjulandin, C. Boni, Yee Chao, Manuel Constenla, Э К Возный and Adriano Rodrigues and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Vladimir Moiseyenko

121 papers receiving 7.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group

2006 1.5k citations Eric Van Cutsem, Vladimir Moiseyenko et al. Journal of Clinical Oncology profile →
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

2012 986 citations Eric Van Cutsem, Josep Tabernero et al. Journal of Clinical Oncology profile →
Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results

2002 855 citations Joyce O’Shaughnessy, David Miles et al. Journal of Clinical Oncology profile →
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

2013 621 citations Yoon‐Koo Kang, Hyun Cheol Chung et al. profile →
Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial

2010 425 citations Jaffer A. Ajani, W. Rodriguez et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Vladimir Moiseyenko

Since Specialization

Citations

This map shows the geographic impact of Vladimir Moiseyenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vladimir Moiseyenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vladimir Moiseyenko more than expected).

Fields of papers citing papers by Vladimir Moiseyenko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vladimir Moiseyenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vladimir Moiseyenko. The network helps show where Vladimir Moiseyenko may publish in the future.

Co-authorship network of co-authors of Vladimir Moiseyenko

This figure shows the co-authorship network connecting the top 25 collaborators of Vladimir Moiseyenko. A scholar is included among the top collaborators of Vladimir Moiseyenko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vladimir Moiseyenko. Vladimir Moiseyenko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract CT253: Results from KEYNOTE-B99: Phase 2 study of first-line (1L) pembrolizumab (pembro) plus investigational agents and chemotherapy (chemo) for extensive-stage small-cell lung cancer (ES-SCLC) 2024 ·Cancer Research ·Delvys Rodríguez‐Abreu, (unknown), Byoung Chul Cho, Tibor Csőszi, (unknown), Veronika Müller, Myung‐Ju Ahn, Dariusz M. Kowalski, Michele Maio, Vladimir Moiseyenko, Alejandro Navarro, (unknown), Andrea S. Fung, (unknown), Heng Zhou, Bin Zhao, Humberto Lara-Guerra, Nir Peled	2
2	Tumor alkalization therapy: misconception or good therapeutics perspective? – the case of malignant ascites 2024 ·Frontiers in Oncology ·Alexey Bogdanov, (unknown), Н. А. Верлов, (unknown), (unknown), Vladimir Burdakov, (unknown), (unknown), Nikita Volkov, Vladimir Moiseyenko	2
3	A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer 2023 ·Investigational New Drugs ·Ilya Tsimafeyeu, Galina Statsenko, (unknown), (unknown), (unknown), (unknown), (unknown), Anastasia Mochalova, (unknown), (unknown), (unknown), (unknown), (unknown), Vladimir Moiseyenko, Sergei Tjulandin	6
4	64O Lenvatinib plus pembrolizumab, pemetrexed, and a platinum (len + pembro + chemo) as first-line therapy for metastatic non squamous non-small cell lung cancer (NSCLC): Phase III LEAP-006 study 2023 ·Immuno-Oncology Technology ·Roy S. Herbst, Byoung Chul Cho, Caicun Zhou, Mauricio Burotto, Manuel Cobo, Mehmet Alı Nahıt Şendur, Vladimir Moiseyenko, Bogdan Żurawski, Ignacio Casarini, Makoto Nishio, Rina Hui, Elvire Pons‐Tostivint, Julia Dudnik, (unknown), Chinyere E. Okpara, Lei Yin, Yun Luo, Niyati Bhagwati, Delvys Rodríguez‐Abreu	3
5	First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study 2022 ·British Journal of Cancer ·Eric Van Cutsem, Iwona Danielewicz, Mark Saunders, Per Pfeiffer, Guillem Argilés, Christophe Borg, Rob Glynne‐Jones, Cornelis J.A. Punt, Agnès J. van de Wouw, М. Yu. Fedyanin, Daniil Stroyakovskiy, Hendrik Kroening, Pilar García‐Alfonso, Harpreet Wasan, Alfredo Falcone, Ronan Fougeray, Anton Egorov, Nadia Amellal, Vladimir Moiseyenko	9
6	Tumor acidity: From hallmark of cancer to target of treatment 2022 ·Frontiers in Oncology ·Alexey Bogdanov, (unknown), (unknown), (unknown), (unknown), Nikita Volkov, Fedor Moiseenko, Vladimir Moiseyenko	100
7	Antitumor efficacy of an isolated hind legperfusion with a pH-increased solution in thePliss’ lymphosarcoma graft rat model 2021 ·SHILAP Revista de lepidopterología ·Alexey Bogdanov, (unknown), Nikita Volkov, Fedor Moiseenko, (unknown), Н. А. Верлов, (unknown), Vladimir Moiseyenko	1
8	Efficacy of Videoendoscopic Inguinal Femoral Lymphadenectomy for Management of Metastatic Skin Melanoma 2021 ·SHILAP Revista de lepidopterología ·(unknown), Fedor Moiseenko, Nikita Volkov, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Vladimir Moiseyenko	0
9	CCND1 and FGFR1 gene amplifications are associated with reduced benefit from aromatase inhibitors in metastatic breast cancer 2020 ·Clinical & Translational Oncology ·Svetlana N. Aleksakhina, (unknown), (unknown), (unknown), (unknown), Alexandr O. Ivantsov, Vladimir Moiseyenko, Evgeny N. Imyanitov, Aglaya G. Iyevleva	6
10	Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial 2019 ·Cancer Chemotherapy and Pharmacology ·Francisco J. Esteva, (unknown), (unknown), Alexey Manikhas, Vladimir Moiseyenko, (unknown), Edvard Zhavrid, (unknown), Daniil Stroyakovskiy, Joanna Pikiel, Alexandru Eniu, (unknown), Andriy Rusyn, B. Tiangco, (unknown), (unknown), (unknown), Justin Stebbing	25
11	“Lazarus Response” to Olaparib in a Virtually Chemonaive Breast Cancer Patient Carrying Gross BRCA2 Gene Deletion 2018 ·Cureus ·Vladimir Moiseyenko, (unknown), Fedor V. Moiseyenko, (unknown), Yuliya Zaytseva, (unknown), (unknown), (unknown), Elena V. Preobrazhenskaya, Anna P. Sokolenko, Evgeny N. Imyanitov	7
12	One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment 2017 ·Annals of Oncology ·Xavier Pivot, Igor Bondarenko, Zbigniew Nowecki, Mikhail Dvorkin, Ekaterina Trishkina, Jin‐Hee Ahn, (unknown), S-A. Im, Tomasz Sarosiek, Sanjoy Chatterjee, Marek Z. Wojtukiewicz, Vladimir Moiseyenko, Yaroslav Shparyk, (unknown), Semiglazov Vf, (unknown), (unknown)	6
13	Quality of Life in the Trastuzumab for Gastric Cancer Trial 2014 ·The Oncologist ·Taroh Satoh, Yung‐Jue Bang, Evgeny Gotovkin, Yasuo Hamamoto, Yoon‐Koo Kang, Vladimir Moiseyenko, Atsushi Ohtsu, Eric Van Cutsem, N. Al-Sakaff, (unknown), Julie Hill, Harald Weber, Hyun Cheol Chung, (unknown)	36
14	Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study 2014 ·Annals of Oncology ·Eric Van Cutsem, C. Boni, Josep Tabernero, Bartomeu Massutí, Gary Middleton, Faysal Dane, Peter Reichardt, Francisco Pimentel, Allen Lee Cohn, Philippe Follana, Michael Clemens, Alberto Zaniboni, Vladimir Moiseyenko, Mark Harrison, Donald Richards, Hans Prenen, Simon Pernot, (unknown), Simon Hitier, P. Rougier	88
15	Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors 2013 ·Investigational New Drugs ·S. Tjulandin, Vladimir Moiseyenko, В. В. Семиглазов, George Manikhas, Maria Learoyd, (unknown), Melissa K. Stuart, Ulrich Keilholz	21
16	Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen breakdown → 2012 ·Journal of Clinical Oncology ·Eric Van Cutsem, Josep Tabernero, Radek Lakomý, Hans Prenen, Jana Prausová, Teresa Macarulla, Paul Ruff, Guy A. Van Hazel, Vladimir Moiseyenko, David Ferry, Joe McKendrick, Jonathan Polikoff, Alexia Tellier, R Castan, Carmen J. Allegra	986
17	Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial breakdown → 2010 ·Journal of Clinical Oncology ·Jaffer A. Ajani, W. Rodriguez, G. Bodoky, Vladimir Moiseyenko, Mikhail Lichinitser, В. А. Горбунова, Ihor Vynnychenko, August Garin, István Láng, S. Falcon	425
18	Phase I/II trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors 2004 ·Annals of Oncology ·Vladimir Moiseyenko, (unknown), (unknown), (unknown), (unknown), (unknown), С. Л. Киселев, Р. В. Орлова, (unknown), (unknown), (unknown), (unknown), (unknown), Barchuk As, (unknown), K.P. Hanson, (unknown)	18
19	Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: Latest results 2001 ·Breast Cancer Research and Treatment ·S. Vukelja, Vladimir Moiseyenko, Robert Leonard, Pierfranco Conté, A. Garin, J. McKendrick, K. Possinger, F Turpin, Ted Vandenberg, Joyce O’Shaughnessy	6
20	Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer 2001 ·Annals of Oncology ·Joyce O’Shaughnessy, Joanne L. Blum, Vladimir Moiseyenko, Stephen E. Jones, David Miles, Diana Bell, R. Rosso, L. Mauriac, B Osterwalder, Hans Ulrich Burger, Siobhan Laws	258

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact